Skip to Main Content

Paper Details

Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.
Ther Adv Med Oncol
0
2023
Author NameAffiliation
Declan G MurphyUniversity of Melbourne
Declan G MurphyPeter MacCallum Cancer Centre
Arun A AzadPeter MacCallum Cancer Centre
Arun A AzadUniversity of Melbourne
  • 1 - 4

Datasets

Release 1.2